Bausch + Lomb Acquiring ISTA Pharmaceuticals

April 9, 2012

In late March, Bausch + Lomb and ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) announced that they have signed a definitive agreement under which Bausch + Lomb will acquire ISTA for $9.10 per share in cash, or a total of approximately $500 million.

Executives anticipate that Bausch + Lomb will help ISTA strengthen its pipeline and market its products by combining ISTA’s portfolio of non-steroidal, anti-inflammatory, allergy, and glaucoma dropsĀ (such as XIBROM and Bromday) to Bausch + Lomb’s portfolio of existing Rx ophthalmology and OTC eye health products. ISTA’s pipeline includes candidates in various stages of development to treat various ocular conditions including inflammation and pain, while Bausch + Lomb’s pipeline of pharmaceutical innovations include the first of a new class of ocular anti-inflammatory agents to come along in decades, and a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

Click here for the full press release.




Jump down to form below to submit your own comments

Comments are closed.